Hims & Hers Health has completed the acquisition of Seaview Enterprises LLC (d/b/a MedisourceRx) on September 5, 2024, acquiring 100% of its membership interests from Nivagen Pharmaceuticals. The transaction was executed through a purchase agreement dated July 5, 2024.As part of the acquisition terms, Hims & Hers issued 976,341 shares of Class A common stock to Nivagen Pharmaceuticals. The company has filed a prospectus supplement on September 9, 2024, to register these resale shares, which was done in accordance with the purchase agreement and under an exemption from Securities Act registration requirements.

Hims & Hers Health has completed the acquisition of Seaview Enterprises LLC (d/b/a MedisourceRx) on September 5, 2024, acquiring 100% of its membership interests from Nivagen Pharmaceuticals. The transaction was executed through a purchase agreement dated July 5, 2024.As part of the acquisition terms, Hims & Hers issued 976,341 shares of Class A common stock to Nivagen Pharmaceuticals. The company has filed a prospectus supplement on September 9, 2024, to register these resale shares, which was done in accordance with the purchase agreement and under an exemption from Securities Act registration requirements.